{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Phase+2&page=13",
    "query": {
      "intervention": "Phase 2",
      "page": 13
    },
    "page_size": 10
  },
  "pagination": {
    "page": 13,
    "page_size": 10,
    "total_count": 37486,
    "total_pages": 3749,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Phase+2&page=14&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Phase+2&page=12&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-25T01:19:47.080Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05139030",
      "title": "Phase 3 Adductor Canal Block With EXPAREL in Subjects Undergoing Primary Unilateral Total Knee Arthroplasty",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Knee Osteoarthritis",
        "Pain Management"
      ],
      "interventions": [
        {
          "name": "bupivacaine liposome injectable suspension",
          "type": "DRUG"
        },
        {
          "name": "Bupivacaine Hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pacira Pharmaceuticals, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 167,
      "start_date": "2022-01-18",
      "completion_date": "2022-07-11",
      "has_results": true,
      "last_update_posted_date": "2024-10-24",
      "last_synced_at": "2026-10-25T01:19:47.080Z",
      "location_count": 6,
      "location_summary": "Little Rock, Arkansas • Pasadena, California • Dayton, Ohio + 3 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "Dayton",
          "state": "Ohio"
        },
        {
          "city": "Bellaire",
          "state": "Texas"
        },
        {
          "city": "Carrollton",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05139030"
    },
    {
      "nct_id": "NCT05746481",
      "title": "Tiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Tiragolumab",
          "type": "DRUG"
        },
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Liza Villaruz, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2023-08-10",
      "completion_date": "2025-11-08",
      "has_results": true,
      "last_update_posted_date": "2026-01-22",
      "last_synced_at": "2026-10-25T01:19:47.080Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05746481"
    },
    {
      "nct_id": "NCT02060981",
      "title": "Evaluation of a Decision Support Tool",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Medication Adherence",
        "Hypertension",
        "Decision Making, Shared",
        "Patient-Centered Outcomes Research"
      ],
      "interventions": [
        {
          "name": "Control",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Interview Only",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Interview plus decision support tool",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "25 Years and older"
      },
      "enrollment_count": 140,
      "start_date": "2014-02",
      "completion_date": "2015-04",
      "has_results": false,
      "last_update_posted_date": "2015-02-18",
      "last_synced_at": "2026-10-25T01:19:47.080Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02060981"
    },
    {
      "nct_id": "NCT04745767",
      "title": "A Study of Different Forms of TAK-994 in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Participants"
      ],
      "interventions": [
        {
          "name": "TAK-994",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 54,
      "start_date": "2021-02-16",
      "completion_date": "2021-04-05",
      "has_results": false,
      "last_update_posted_date": "2021-04-22",
      "last_synced_at": "2026-10-25T01:19:47.080Z",
      "location_count": 2,
      "location_summary": "Tempe, Arizona • Lincoln, Nebraska",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04745767"
    },
    {
      "nct_id": "NCT01458067",
      "title": "A Phase I/IIa, First Time in Human, Study of GSK2636771 in Subjects With Advanced Solid Tumors With Phosphatase and Tensin Homolog (PTEN) Deficiency",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "GSK2636771",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2011-11-10",
      "completion_date": "2016-02-25",
      "has_results": false,
      "last_update_posted_date": "2018-07-24",
      "last_synced_at": "2026-10-25T01:19:47.080Z",
      "location_count": 4,
      "location_summary": "New Haven, Connecticut • Oklahoma City, Oklahoma • Nashville, Tennessee + 1 more",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01458067"
    },
    {
      "nct_id": "NCT02953665",
      "title": "Safety and Efficacy of Liraglutide in Parkinson's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Parkinson Disease"
      ],
      "interventions": [
        {
          "name": "Liraglutide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cedars-Sinai Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "25 Years to 85 Years"
      },
      "enrollment_count": 63,
      "start_date": "2017-04-03",
      "completion_date": "2022-08-03",
      "has_results": true,
      "last_update_posted_date": "2024-03-07",
      "last_synced_at": "2026-10-25T01:19:47.080Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02953665"
    },
    {
      "nct_id": "NCT03091400",
      "title": "Recall Enhancement Through Treatment With Atomoxetine in MS (RETAIN-MS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Memory Disorders",
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Atomoxetine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Icahn School of Medicine at Mount Sinai",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "21 Years to 60 Years"
      },
      "enrollment_count": 11,
      "start_date": "2017-03-16",
      "completion_date": "2018-06-11",
      "has_results": true,
      "last_update_posted_date": "2020-03-13",
      "last_synced_at": "2026-10-25T01:19:47.080Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03091400"
    },
    {
      "nct_id": "NCT03473236",
      "title": "Phase 1A Safety Trial of Inhaled PK10571 (GB002)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Safety Issues"
      ],
      "interventions": [
        {
          "name": "GB002",
          "type": "DRUG"
        },
        {
          "name": "Generic Dry Powder Inhaler",
          "type": "DEVICE"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 66,
      "start_date": "2017-09-06",
      "completion_date": "2018-12-03",
      "has_results": true,
      "last_update_posted_date": "2020-06-09",
      "last_synced_at": "2026-10-25T01:19:47.080Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03473236"
    },
    {
      "nct_id": "NCT00060411",
      "title": "A Phase I, Pharmacological, and Biological Study of OSI-774 in Combination With FOLFOX 4 (5-FU, Leucovorin, and Oxaliplatin) and Bevacizumab (Avastin) in Patients With Advanced Colorectal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Mucinous Adenocarcinoma of the Colon",
        "Mucinous Adenocarcinoma of the Rectum",
        "Recurrent Colon Cancer",
        "Recurrent Rectal Cancer",
        "Signet Ring Adenocarcinoma of the Colon",
        "Signet Ring Adenocarcinoma of the Rectum",
        "Stage IIIA Colon Cancer",
        "Stage IIIA Rectal Cancer",
        "Stage IIIB Colon Cancer",
        "Stage IIIB Rectal Cancer",
        "Stage IIIC Colon Cancer",
        "Stage IIIC Rectal Cancer",
        "Stage IVA Colon Cancer",
        "Stage IVA Rectal Cancer",
        "Stage IVB Colon Cancer",
        "Stage IVB Rectal Cancer"
      ],
      "interventions": [
        {
          "name": "erlotinib hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "leucovorin calcium",
          "type": "DRUG"
        },
        {
          "name": "oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "bevacizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2003-06",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-09-30",
      "last_synced_at": "2026-10-25T01:19:47.080Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00060411"
    },
    {
      "nct_id": "NCT01307644",
      "title": "Web-Based Weight Loss & Weight Maintenance Intervention for Older Rural Women, Also Known as Women Weigh-in for Wellness",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Overweight and Obesity"
      ],
      "interventions": [
        {
          "name": "Experimental: Web-based only (WO) weight intervention",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Experimental: WO plus peer-led discussion board (WD)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Experimental: WO & professional email counseling (WE)",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Nebraska",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "69 Years",
        "sex": "FEMALE",
        "summary": "40 Years to 69 Years · Female only"
      },
      "enrollment_count": 301,
      "start_date": "2011-05-01",
      "completion_date": "2016-08-01",
      "has_results": false,
      "last_update_posted_date": "2023-09-06",
      "last_synced_at": "2026-10-25T01:19:47.080Z",
      "location_count": 1,
      "location_summary": "Omaha, Nebraska",
      "locations": [
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01307644"
    }
  ]
}